The systemic therapies available for the management of Psoriasis (PsO) patients who
cannot be treated with more conservative options, such as topical agents and/or …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

Background Little data are available about the safety of TNF‐α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …

Introduction: Biologics are highly effective, important treatment options for moderate-to-
severe psoriasis. Biologics are well tolerated and have few side effects. However, the use of …

The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV
patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis …

Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …

Background HBV and HCV reactivation have been widely reported in patients undergoing
immunosuppressive therapy (IT); however, few data are available on the risk of reactivation …

Background Ustekinumab, an interleukin (IL)‐12 and IL‐23 blocker, has emerged as a new
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …

The use of anti‐tumor necrosis factor (TNF)‐α therapy in patients with psoriasis who are
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …

Background Issues concerning the potential risks of reactivating chronic hepatitis B virus
arise when the use of anti‐Tumour Necrosis Factor‐α (TNFα) agents is imperative in patients …